What does Mounjaro mean — and why does the name matter?

Where does the name Mounjaro come from?

Brand names for medicines are chosen by pharmaceutical companies through a tightly regulated process. Eli Lilly registered "Mounjaro" as a trade name for tirzepatide when seeking approval from regulators including the MHRA in the UK. The name has no dictionary meaning in English or Latin, unlike older drug names that were often derived from their mechanism or chemical class. It is purely a proprietary identifier, chosen in part because it is distinctive, not already trademarked, and unlikely to be confused with other medicine names at the point of prescribing or dispensing.

Tirzepatide (the international non-proprietary name, or INN) is the word that carries the scientific weight. The suffix "-tide" signals that it belongs to the peptide family; the "tirze" prefix is a condensed reference to its structural lineage. When pharmacists, GPs and prescribers write or read a prescription, tirzepatide is the name that matters clinically. Mounjaro is what appears on the box in your fridge door.

You may occasionally see the name "Zepbound" mentioned online. That is the US brand name for the same molecule, tirzepatide, used specifically for obesity there. It does not exist as a UK product; in the UK, tirzepatide for weight management is sold only as Mounjaro. If you'd like a fuller overview of the medicine itself, our guide to what Mounjaro is covers the licensed indications and background in detail.

What makes tirzepatide different from other weight-loss injections?

The reason Mounjaro attracted significant clinical interest is its dual mechanism. Most GLP-1 receptor agonists (including semaglutide (Wegovy)) act on a single receptor pathway. Tirzepatide activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously. It is the only dual GIP and GLP-1 receptor agonist licensed for weight management in the UK.

Both receptors play a role in appetite regulation, gastric emptying and blood-sugar control. Stimulating them together appears to produce a greater effect on appetite suppression and satiety than either pathway alone. If you're curious about the biological detail of how that translates to weight loss, the page on what Mounjaro does to the body goes deeper into that physiology.

NICE, in its appraisal of tirzepatide (TA1026, published December 2024), noted that the indirect comparisons in clinical evidence favoured tirzepatide over semaglutide 2.4 mg, a finding supported by the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025. That said, which medicine is appropriate for any individual is a clinical question, not one resolved by a name or a mechanism alone.

What does the clinical evidence say about how it works in practice?

SURMOUNT-1 (the pivotal phase 3 trial) followed thousands of adults with obesity over 72 weeks. Participants on the 15 mg maintenance dose lost an average of around 20–21% of their body weight alongside a reduced-calorie diet and increased activity. The NHS tirzepatide medicines page provides a patient-level summary of how the medicine works, its common side effects and what to expect.

Mounjaro is injected once weekly using a pre-filled KwikPen. Each pen contains four weekly doses. Treatment starts at 2.5 mg (a dose chosen for tolerability, not therapeutic effect) and is titrated upward by the prescriber, typically in four-week steps, through 5, 7.5, 10, 12.5 and 15 mg. The prescriber decides the pace of titration based on how well the medicine is tolerated, not a fixed schedule the patient controls.

Side effects are predominantly gastrointestinal: nausea, constipation, diarrhoea and indigestion are most commonly reported, especially after a dose increase. They tend to settle within a couple of weeks for most people. For a more detailed look at what appetite suppression feels like in practice, the piece on what suppression means on Mounjaro explains it in plain terms.

Who can be prescribed Mounjaro in the UK?

The UK licence covers adults with a BMI of 30 or above, or those with a BMI of 27 or above who have at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. BMI is a starting point, not the whole picture; a prescriber reviews the individual's full health history before deciding whether Mounjaro is appropriate.

Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA requires additional monitoring of its safety data. It is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or a history of pancreatitis should discuss this carefully with their prescriber before starting.

Our tirzepatide overview sets out the eligibility criteria in full. For a broader look at the weight-loss treatments available in the UK, including how Mounjaro sits alongside other licensed options, that page covers the landscape without the prescribing detail. A note on cost: private treatment pricing varies considerably by dose and provider; our Mounjaro cost guide explains what the market looks like and what a legitimate private price typically includes. If after reading you'd like a clinical conversation about whether Mounjaro is right for you, our prescribers are straightforward to reach, and if you have seen references to taking smaller amounts than the standard doses, our page on what microdosing Mounjaro means explains the practice clearly before you speak to a clinician. Speak to our prescribers through a free consultation and a named clinician will review your answers the same day.